Clinical Trials Browser

Phase 1 × INDUSTRY × omburtamab I-131 × Clear all

NCT00089245 2023-12-26

Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Brain Neoplasms, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Meningeal Carcinomatosis, Desmoplastic Small Round Cell Tumor